[ad_1]
It was announced on Tuesday that the Covid-19 Committee of Experts in India has approved Covaxin for emergency use in children aged 2-18.
The official expert group said in a statement: “After detailed review, the subject-matter expert committee recommends granting a market authorization to restrict the use of vaccines in the 2 to 18-year-old age group in emergency situations.” The vaccine will be vaccinated in two separate doses with 20 days apart.
Bharat Biotech, a Hyderabad-based company, completed Covaxin’s second and third phases of trials on children under 18 last month. The Committee of Experts imposes certain conditions on the emergency use authorization. The company must provide security data every 15 days for the first two months and monthly thereafter.
Please also read:
>> Covid-19: India approves Cadila’s 3 dose-free vaccines
>> India sets a new record for Covid vaccination with 20 million doses per day
In early August, the government approved the emergency use of ZyCov-D, a vaccine produced by Indian pharmaceutical giant Zydus Cadila for children of the same age.
However, the World Health Organization (WHO) still needs to grant emergency use authorization to Covaxin. Bharat Biotech has submitted the necessary documents to WHO in July and is awaiting its approval.
[ad_2]
Source link